&w=3840&q=100)
Study finds men more likely to fall sick, die from 3 common health issues
However, compared to women, men were found to be less likely to seek medical care and adhere to treatment for these common health conditions due to norms related to masculinity and healthcare financing.
Men were also more likely to smoke, while women were more likely to be obese and engage in unsafe sex, the study, published in the journal PLOS Medicine, found.
The research highlights sex-based differences at each step of the "health pathway", which includes being exposed to a risk factor -- such as smoking -- developing a condition, diagnosis, treatment and death, study authors said.
"Most of these differences are not explained by sex (biology) alone, but by socially-constructed gender -- highlighting the importance of taking a gender justice approach to reducing health inequities. A gender analysis can help to shape systems of health for all," Kent Buse, co-founder of Global 50/50, a UK-based research initiative seeking to achieve gender equality in global health, said.
The findings are in line with those from previous studies showing men using fewer preventive, diagnostic, and treatment services for conditions such as HIV and COVID-19, compared to women.
The study found that men and women received different care for hypertension in 200 countries.
Also in 39 countries such as Afghanistan, Bangladesh, Ecuador and Ethiopia, men and women received different care for diabetes, and in 76 countries, including Australia, Chile, Italy and Lesotho, they received different care for HIV.
Overall, the authors said strategies need to be developed for encouraging men to participate in preventive and health care services.
"We have long advocated the benefits of publishing sex disaggregated data. As our Gendered Health Pathways demonstrates, such data can reveal where the health journeys of men and women diverge be it in relation to the risk factors they are exposed to, their health care seeking behaviours or their experiences in health care systems. That is an important first step towards health equity," Buse said.
"Males had significantly higher prevalence rates of conditions in 56 per cent of countries for HIV and AIDS, 30 per cent for diabetes, and four per cent for hypertension," the authors wrote.
"Females, on the other hand, had significantly higher prevalence rates of conditions in 14 per cent of countries for HIV and AIDS, five per cent for diabetes, and only in India for hypertension," they wrote.
Further, compared to women, death rates were found to be higher among men in 131 countries (64 per cent) for HIV/AIDS, 107 for hypertension (53 per cent) and 100 for diabetes (49 per cent).
Death rates among women were higher, compared to men, in 25 countries for HIV/AIDS, nine for diabetes and only in the United Arab Emirates for hypertension, the study found.
Women were also seen to have higher rates of diagnosis, treatment, and control.
For the study, data on risk factors, disease prevalence, and death rates were obtained from the Global Burden of Disease (GBD) dataset.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Mint
35 minutes ago
- Mint
Indian contract drug makers timed their IPOs right. But is the business worth the premium?
An anticipated shift in the global pharmaceutical supply chain away from China has investors excited about Indian contract research, development and manufacturing organisations (CRDMOs), companies that offer services from early-stage drug discovery to late-stage drug development. Export-focused CRDMOs including Anthem Biosciences, Sai Life Sciences and Divi's Laboratories are trading at expensive valuations, reflecting investor enthusiasm as innovator drug companies look at diversifying and derisking their operations. However, experts cautioned that while CRDMOs are expected to post high growth, their financial performances have yet to reflect it. Bengaluru-based Anthem Biosciences made a stellar debut on the stock exchanges on 21 July, listing on the National Stock Exchange at a premium of 27 percent over its initial public offering price of ₹ 570. The IPO, with an issue size of ₹ 3,395.79 crore, was subscribed 67.42 times. Anthem's stock traded at a price-to-earnings (PE) ratio of 93.24 on 25 July. 'The good news is that… China is a behemoth. So, we have that much headroom to grow,' Ajay Bhardwaj, managing director and chief executive officer, told Mint earlier. About 65% of India's imported bulk drugs and advanced drug intermediates worth $3.5 billion in FY25 came from China, according to the commerce ministry. The government wants to strengthen local manufacturing through an upgraded drugs production-linked incentive scheme as it pushes for self-sufficiency in bulk drugs that go into manufacturing medicines. The Indian CRDMO industry today is worth $3-3.5 billion, making up only 2-3% of the global CRDMO market, which is worth $145 billion. It grew at a compound annual growth rate of 15% from 2019-2024, according to a recent report by BCG and IPSO. The industry is at a tipping point, with strong fundamentals and massive headroom to grow, fueled by competitive advantage in small molecule capabilities, faster startup time, focus on quality and cost advantages, the report noted. Unlike CRDMOs, CDMOs (contract development and manufacturing organisations) are typically involved in manufacturing already commercialised drugs. Sai Life Sciences, which made its market debut in December 2024, traded at ₹ 837 on 25 July, close to its high of about ₹ 851, valuing the company at roughly 102 times trailing earnings and about 8.2 times book value. Divi's Laboratories and Syngene International also traded at premiums, at a PE ratio of 80.31 and 55.09, respectively. In comparison, generic pharmaceutical giants are valued relatively modestly: Sun Pharmaceutical Industries trades at a PE ratio of 37.37, Dr Reddy's Laboratories at 18.84, and Cipla at 23.53. Sai Life Sciences shares are up over 18% since listing on the NSE. Divi's Laboratories gained 35.56% from 30 July 2024 to 28 July 2025, Piramal Pharma rose 20.36%, while Syngene International's shares were down 12.72%. Syngene International, a unit of biopharmaceutical company Biocon, kicked off this fiscal's earnings season last week. It posted an 11% year-on-year rise in revenue from operations to ₹ 875 crore for Q1, a robust start compared to its FY25 performance (4% revenue growth YoY). The management maintained its expectation of revenue growth in the mid‑teens for FY26. Sai Life Sciences delivered 16% revenue growth to ₹ 1,695 crore in FY25. Divi's reported a 19% year-on-year rise in full-year revenue to ₹ 9,360 crore in FY25, while net profit surged 37% to ₹ 2,191 crore. Divi's is expected to post revenue growth of 18% year-on-year in Q1FY26, according to brokerage BNP Paribas. 'The Indian CDMO sub-sector presents a highly promising opportunity as investors view it as a direct beneficiary of the China+1 thematic,' Sunil Khaitan, managing director leading financing in India at Goldman Sachs, told Mint. 'We expect the capital markets activity in this space to further accelerate over the next 6-12 months.' The China-plus one theme – to diversify supply chains and reduce overdependence on China – is a key driver, but it's not just that. CRDMOs are on an aggressive capacity expansion track as they anticipate winning over more clients in the future and bank on technological niches to cater to biotech companies as demand for new technologies and drugs grows. Anthem has expertise in new chemical entities as well as biologics (drugs made from living organisms or their components) and capabilities to work on RNAi (a gene regulatory mechanism), antibody drug conjugates that target and kill cancer cells, peptides (short chains of amino acids), lipids, and oligonucleotides (synthesised nucleic acids). OneSource Specialty Pharma, a subsidiary of Strides Pharma, which listed in January, expects its focus on niche areas such as biologics, drug substances, injectables, and drug-device combinations to drive growth. Its offerings in drug-device combinations, particularly for GLP-1s (hormones that regulate blood sugar levels), which are often sold in pen-filled devices, is expected to be a major growth opportunity. 'We are currently executing a 5x expansion of our cartridge-filling capabilities to meet our customer demand and which will significantly boost future revenue,' CEO Neeraj Sharma told Mint in an emailed response. Anthem Biosciences and Sai Life Sciences did not respond to Mint's queries. Investors are looking at CRDMOs not just for potential growth driven by these tailwinds but also as diversification of their portfolios, experts said. Opportunities in traditional pharma companies with a focus on domestic formulations and US generics are drying up because of a slowdown in new approvals and regulatory issues. 'The investor would like to have exposure to companies and segments which have the potential for high growth and themes of shifting manufacturing from China to India,' Tausif Shaikh, healthcare and pharma analyst at BNP Paribas, told Mint. While CRDMOs have reported steady, mid-teen revenue growth, their performance has not been encouraging enough even as valuations remain expensive, Shaikh pointed out. Unlike sectors such as healthcare services, where one can gauge a company's performance based on metrics like hospital bed occupancy and average revenue per bed, for contract drug manufacturers, management commentary is the main indicator of the company's expected growth and performance, said Shaikh. Most companies report an uptick in interest from innovators to hire their services and have embarked on aggressive capacity expansion. Syngene plans to boost its biologics manufacturing footprint in FY26 through its newly acquired US facility for $36.5 million. Divi's Laboratories is undertaking a ₹ 650-700 crore capacity expansion at its existing facilities, while Sai Life Sciences has completed the second phase of its Bidar Unit IV capacity expansion for small-molecule active pharmaceutical ingredients and intermediates. On the back of this, the growth outlook remains strong. "Earnings are expected to be strong for export-oriented CDMOs for the next 2-3 years considering the capex projects and potential addition of new molecules,' Shrikant Akolkar, pharma equity research analyst at brokerage Nuvama, told Mint. However, the CDMO business is non-linear, Akolkar said, adding that one must pay attention to the annual performance and not a couple of quarters of number misses.


Time of India
an hour ago
- Time of India
New Covid variant symptoms seen in US amid surge in summer wave: Check symptoms and states at the highest risk
As many as 26 states in US including Virginia, North Carolina, and Texas are witnessing a surge in the new variant in Covid. The worrying data from the Centers for Disease Control and Prevention show a summer surge of Covid-19, with cases increasing across the country. "COVID-19 laboratory percent positivity is increasing nationally," according to the Centers for Disease Control and Prevention (CDC) website. "Emergency department visits for COVID-19 are increasing among young children 0-4 years old," though the CDC noted that emergency room visits are "low" overall. Covid cases rising in US Covid-19 numbers are increasing in Massachusetts, and in multiple states across the country. The CDC in its latest report said the number of cases is now growing or likely growing in at least 26 states and Washington, D.C. COVID-related emergency room visits for young kids are also the highest they've been since March, according to the data. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Villas in Dubai | Search Ads Get Info Undo The latest COVID-19 strain is known as "Nimbus." As of early June, the new strain known as NB.1.8.1, or "Nimbus," made up 37% of COVID-19 cases nationwide. ALSO READ: Why New Yorkers may have to pay sky-high electricity bill from next month "We now know that there's a winter spike and then there's a summer spike," he said. "And every year, I just looked last night, the number of deaths, the number of hospitalizations, is gradually going down each season. So that's the good news," CBS News chief medical correspondent Dr. Jon LaPook told "CBS Mornings". He warned that people should not ignore the increase in Covid cases. Live Events "If it strikes you, especially for the vulnerable, and we're talking about very young children under age of 4, the elderly, people who are immunocompromised — there are millions of people who are immunocompromised out there — they can really get sick," LaPook said. COVID spikes used to mostly hit in winter, however now the virus is showing up twice a year. What should you know about Nimbus strain? Nimbus strain was first detected in China in January 2025 but accounted for about 0% of cases in the United States until May. The latest COVID variants, nicknamed Nimbus and Stratus, are "no more deadly" than previous variants, LaPook said. The Nimbus strain spreads fast and often causes sore throats that feel sharp or painful, this condition is also know as 'razor blade throat.' It's now dominant in most states. So far, it doesn't appear to cause more serious illness. ALSO READ: Trump to prosecute Kamala Harris, Beyoncé, Oprah Winfrey? US President reiterates explosive warning Virologists describe Nimbus as a 'slightly upgraded' version of its predecessor. While there is no evidence it causes more severe disease, it appears to be highly transmissible. Reported symptoms of NB.1.8.1 are similar to other COVID-19 strains. However, there is one distinctive complaint- a severe sore throat, sometimes described as 'razor-blade throat fatigue.' Other symptoms may include: Mild cough Fever Muscle aches Nasal congestion Should you get a Covid booster? Health experts say that updated COVID-19 vaccines remain the best protection against severe illness. Vaccination rates vary widely by state, and health officials continue to urge eligible individuals to stay current with their shots. The CDC website still says the COVID-19 vaccine helps protect you from "severe illness, hospitalization and death," there have been some shifts in recommendations. The American College of Obstetricians and Gynecologists, for example, says pregnant people should get vaccinated. The CDC has advised using "shared clinical decision-making" when considering the COVID-19 vaccine for healthy children. ALSO READ: 'Made me a meme': Ex-Astronomer CEO Andy Byron to sue Coldplay over viral kiss cam controversy. Chris Martin reacts For adults aged 18 and older, the agency continues to recommend the 2024–2025 COVID-19 vaccine, emphasizing its importance for those 65 and older, individuals at high risk of severe illness, or those who have never been vaccinated against COVID-19. Where COVID-19 cases are growing in US? Covid-19 cases are growing in Arkansas, Hawaii, Illinois, Iowa, Kentucky, North Carolina, Ohio, Pennsylvania, Texas and Virginia. ALSO READ: Largest great white shark ever captured in Florida leaves scientists stunned. It measures 13.8 feet and weighs 1,653 pounds How can you stay safe? -Get a booster if it is more than six months since your last dose. Old age people, people with weak immune systems need extra protection. -Wear mask in crowded places like N95 or KN95 especially in areas that have poor air circulation. -Keep at-home tests ready and take one, if you feel sick or if you were exposed to the virus. If it's positive, isolate for five days. -Use air purifiers, improve the air flow in the indoors. -Wash hands often, use sanitizer. Don't touch your face after being in public. Watch for signs like fever, fatigue, and sore throat. Act fast if symptoms show up.


Time of India
2 hours ago
- Time of India
World Hepatitis Day: Early symptoms and spread of Hepatitis B
World Hepatitis Day is observed each year on 28 July to raise awareness of viral hepatitis, an inflammation of the liver that causes severe liver disease and liver cancer. This year's theme is Hepatitis: Let's Break It Down, shows urgency, a prompt action to dismantle the financial, social stigma that is attached to this condition against eliminating it. According to data published by the World Health Organisation (WHO) 304 million people are living with chronic hepatitis B and C since 2022, and 1.3 million people died of it in 2022 itself. Dr. Catharia Beohme, officer-in-charge of the WHO South-east Asia region, clearly stated that Viral hepatitis continues to be a needless suffering among thousands of innocent people, silently attacking our liver, spreading cancer, and causing hundreds of thousands of preventable deaths each year. She said, 'Across the Region, an estimated 61 million people live with hepatitis B, and 9 million with hepatitis C. Our Region bears one of the highest burdens of chronic viral hepatitis globally, yet most people living with the disease remain undiagnosed and untreated.' this is a global burden we are all suffering under and this needs to be addressed as son as possible. According world hepatitis alliance, Hepatitis is the world's deadliest virus after COVID-19, and more than 300 million people are living with hepatitis. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Susan Boyle Is Now so Thin and Looks Beautiful! Undo Surprisingly, it is the leading cause of liver cancer. What is Hepatitis Hepatitis is an inflammatory disease of the liver that is caused by infectious viruses and Noninfectious agents, leading to a range of health problems, including severe liver damage and cancer, which we all know how deadly it is. There are 5 major strains of this virus,s namely A, B, C,D and E. While the other is no less than the first, particularly, each of them offer a different kind of liver disease. In particular, types B and C lead to chronic disease in hundreds of millions of people and together are the most common cause of liver cirrhosis, liver cancer and viral hepatitis-related deaths. What are the symptoms of Hepatitis People with hepatitis may or may not exhibit symptoms. Major symptoms include: Fever Malaise Loss of appetite Nausea Diarrhoea Abdominal discomfort Jaundice Dark-coloured urine Specifically, hepatitis B, C, and D can cause liver infection, which can later develop in liver cirrhosis or liver cancer. How to protect ourselves against Hepatitis B and its spread Hepatitis B is an infection of the liver caused by the hepatitis B virus. The infection can be acute (short and severe) or chronic (long term). Hepatitis B can be prevented with a safe and effective vaccine. The vaccine is usually given soon after birth with boosters a few weeks later. It offers nearly 100% protection against the virus. Ways it can be contracted Hepatitis B can commonly spread from mother to her child at birth or through horizontal transmission, especially from an infected child to an uninfected child during the first 5 years of their life. Hepatitis B is also spread by an infected person's needle, tattooing, piercing and exposure to infected blood and body fluids, such as saliva and menstrual, vaginal, and seminal fluids. Transmission of the virus may also occur through the sharing or reuse of contaminated needles and syringes or sharp objects, either in health care settings, in the community or among persons who inject drugs. Sexual transmission is more prevalent in unvaccinated persons with multiple sexual partners. Is it easily diagnosed? Its diagnosis requires a lab test, as its symptoms can mimic other hepatitis symptoms as well. WHO recommends screening in high-prevalence areas, pregnant women, blood donors, and high-risk groups. Only 13% of infected people knew their status in 2022, and 3% were receiving treatment. Coinfection with HIV occurs in about 1% of Hepatitis B cases; treatment for HIV often also treats Hepatitis B (WHO) Hepatitis, especially Hepatitis B remains a significant global health challenge, affecting millions, to reduce this global burden, this is an earnest request to spread as much information about it as possible, as this deadly disease requires a coordinated global action.